CHICAGO, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Vanqua Bio, a clinical-stage biopharmaceutical company, announced that the company will present at the 8th Annual Complement-Based Drug Development Summit, which will be held in... read more →
VQ-101 is the first small molecule to demonstrate > 75% activation of the lysosomal enzyme glucocerebrosidase (GCase) in humans In healthy volunteers, VQ-101 was well tolerated and achieved peripheral and... read more →
CHICAGO, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Vanqua Bio, a biopharmaceutical company dedicated to discovering and developing next-generation medicines for the treatment of neurodegenerative diseases, announced today that it will participate in... read more →
CHICAGO, June 20, 2024 (GLOBE NEWSWIRE) -- Vanqua Bio, a biopharmaceutical company dedicated to discovering and developing next-generation medicines for the treatment of neurodegenerative diseases, announced today that it will participate in... read more →
VQ-101 is a potent allosteric activator of glucocerebrosidase (GCase) The Phase 1 program aims to demonstrate VQ-101’s pharmacodynamic effects in healthy volunteers and Parkinson’s patients CHICAGO, April 09, 2024 (GLOBE... read more →
February 27, 2024 07:30 ET (GLOBE NEWSWIRE) -- Vanqua Bio today announced that the company will participate in the AD/PD™ 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders,... read more →
CHICAGO, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Vanqua Bio today announced that its development candidate VQ-101, a best-in-class brain-penetrant small molecule allosteric activator of glucocerebrosidase (GCase), will enter clinical development in the... read more →
CHICAGO, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Vanqua Bio, a biopharmaceutical company focused on discovering and developing next-generation medicines that have the potential to transform the lives of patients with... read more →
CHICAGO, March 22, 2023 (GLOBE NEWSWIRE) -- Vanqua Bio, a biopharmaceutical company focused on discovering and developing next-generation medicines that have the potential to transform the lives of patients with neurodegenerative... read more →
Tune in to hear John Flavin and the Chicago Biomedical Consortium Entrepreneurial Fellows engage with Jim, aiming to learn more about the life sciences industry and the different means of... read more →